Reviews
31 March 2015
Vol. 66 No. 4 (2014)
https://doi.org/10.4081/reumatismo.2014.799

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis.
2502
Views
2249
Downloads

Authors

M. Rossini
maurizio.rossini@univr.it
Rheumatology Unit, University of Verona, Italy.
O Viapiana
Rheumatology Unit, University of Verona, Italy.
G. Orsolini
Rheumatology Unit, University of Verona, Italy.
E. Fracassi
Rheumatology Unit, University of Verona, Italy.
L. Idolazzi
Rheumatology Unit, University of Verona, Italy.
D. Gatti
Rheumatology Unit, University of Verona, Italy.
S. Adami
Rheumatology Unit, University of Verona, Italy.
M. Govoni
Rheumatology Unit, University of Ferrara, Italy.
Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite



Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?. (2015). Reumatismo, 66(4), 285-303. https://doi.org/10.4081/reumatismo.2014.799

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.